全文获取类型
收费全文 | 2019篇 |
免费 | 109篇 |
国内免费 | 76篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 171篇 |
妇产科学 | 26篇 |
基础医学 | 223篇 |
口腔科学 | 58篇 |
临床医学 | 254篇 |
内科学 | 491篇 |
皮肤病学 | 73篇 |
神经病学 | 59篇 |
特种医学 | 391篇 |
外科学 | 109篇 |
综合类 | 44篇 |
预防医学 | 88篇 |
眼科学 | 19篇 |
药学 | 85篇 |
2篇 | |
肿瘤学 | 110篇 |
出版年
2023年 | 5篇 |
2022年 | 7篇 |
2021年 | 11篇 |
2020年 | 14篇 |
2019年 | 16篇 |
2018年 | 31篇 |
2017年 | 22篇 |
2016年 | 22篇 |
2015年 | 39篇 |
2014年 | 47篇 |
2013年 | 60篇 |
2012年 | 40篇 |
2011年 | 37篇 |
2010年 | 90篇 |
2009年 | 85篇 |
2008年 | 53篇 |
2007年 | 87篇 |
2006年 | 52篇 |
2005年 | 53篇 |
2004年 | 26篇 |
2003年 | 19篇 |
2002年 | 29篇 |
2001年 | 40篇 |
2000年 | 29篇 |
1999年 | 28篇 |
1998年 | 128篇 |
1997年 | 155篇 |
1996年 | 131篇 |
1995年 | 108篇 |
1994年 | 114篇 |
1993年 | 97篇 |
1992年 | 28篇 |
1991年 | 35篇 |
1990年 | 36篇 |
1989年 | 54篇 |
1988年 | 46篇 |
1987年 | 42篇 |
1986年 | 49篇 |
1985年 | 45篇 |
1984年 | 26篇 |
1983年 | 15篇 |
1982年 | 24篇 |
1981年 | 29篇 |
1980年 | 25篇 |
1979年 | 4篇 |
1978年 | 11篇 |
1977年 | 18篇 |
1976年 | 25篇 |
1975年 | 14篇 |
1966年 | 1篇 |
排序方式: 共有2204条查询结果,搜索用时 15 毫秒
111.
Leaf AN Wolf BC Kirkwood JM Haselow RE 《Medical oncology (Northwood, London, England)》2000,17(1):47-51
This study of etoposide in thyroid cancer was designed to determine the activity and toxicity of etoposide in a variety of
inoperable, thyroid hormone insensitive, and radio-iodine resistant primary cancers of the thyroid. The patients were required
to have an ECOG performance status of at least 3 and no previous exposure to chemotherapy. The etoposide was given at a dose
of 140 mg/m2 daily for 3 days and every 3 weeks until progression. The study was closed after 18 months because of poor accrual. There
were no responses seen among the 10 patients accrued. The toxicity was primarily hematologic. There was no evidence of activity
of etoposide in thyroid carcinoma, although this study lacked significant power because of the poor accrual. 相似文献
112.
113.
114.
115.
Mushroom worker's lung disease 总被引:1,自引:0,他引:1
116.
三尖杉树皮粗提取物中的一个新生物碱—高三尖杉酯碱酰胺(homoharringtonamide)的结构,经质谱—质谱分析,初步建议为16。类似的酰胺类生物碱,例如三尖杉碱酰胺(cephalotaxamide,6)、11-羟基三尖杉碱酰胺(11-hydroxycephalotaxamide,9)、三尖杉酯碱酰胺(harfingtonamide,14)或异三尖杉酯碱酰胺(isoharringtonamide,15)也可能存在,后三者(9,14,15)尚未见报道。 相似文献
117.
Marcelo A Pinto Marcio F Chedid Leo Sekine re P Schmidt Rodrigo P Capra Carolina Prediger Jo o E Prediger Tomaz JM Grezzana-Filho Cleber RP Kruel 《World journal of gastrointestinal surgery》2019,11(1):11-18
Liver transplant(LT) is the primary treatment for patients with end-stage liver disease. About 25000 LTs are performed annually in the world. The potential for intraoperative bleeding is quite variable. However, massive bleeding is common and requires blood transfusion. Allogeneic blood transfusion has an immunosuppressive effect and an impact on recipient survival, in addition to the risk of transmission of viral infections and transfusion errors, among others.Techniques to prevent excessive bleeding or to use autologous blood have been proposed to minimize the negative effects of allogeneic blood transfusion.Intraoperative reinfusion of autologous blood is possible through previous selfdonation or blood collected during the operation. However, LT does not normally allow autologous transfusion by prior self-donation. Hence, using autologous blood collected intraoperatively is the most feasible option. The use of intraoperative blood salvage autotransfusion(IBSA) minimizes the perioperative use of allogeneic blood, preventing negative transfusion effects without negatively impacting other clinical outcomes. The use of IBSA in patients with cancer is still a matter of debate due to the theoretical risk of reinfusion of tumor cells. However, studies have demonstrated the safety of IBSA in several surgical procedures, including LT for hepatocellular carcinoma. Considering the literature available to date, we can state that IBSA should be routinely used in LT, both in patients with cancer and in patients with benign diseases. 相似文献
118.
119.
Liu JM; Chen YM; Chao Y; Liu SM; Tiu CM; Wu HW; Chiou TC; Hsieh RK; Chen LT; Whang-Peng J 《Japanese journal of clinical oncology》1998,28(7):431-435
BACKGROUND: To evaluate the efficacy and toxicity of cisplatin/etoposide
continuous infusion chemotherapy for cancer of unknown primary site in
Taiwan, a region with a high prevalence of endemic viral infections.
METHOD: Between April 1994 and February 1996, 20 patients with a diagnosis
of CUPS were treated, including 15 males and five females, of average age
63.3 years (range 41-83 years). Continuous intravenous infusion of
etoposide 80 mg/m2 and cisplatin 25 mg/m2 was given for 3 days every 3
weeks. Pretreatment tumor marker and viral serology studies were performed
for baseline evaluation. Nearly two-thirds of the patients had poorly
differentiated carcinoma. The average number of metastatic sites was 2.65
(range 1-4), with liver and lymph node involvement predominating. RESULTS:
The overall response rate was 25% (95% CI 17.7-32.3%); 30.7% for poorly
differentiated cancers and 25% for well differentiated cancers. Median
survival was 4 months (range 1-12 months), 4.8 months for patients
attaining partial response. Toxicity was moderate, grade 3 and 4
neutropenia occurred in 55% and grade 3 and 4 thrombocytopenia in 40%;
other toxicities were mild. CA125 and CA199 were elevated in more than 50%
of patients. Viral serology studies were not significantly different from
those of the indigenous population. CONCLUSION: Etoposide and cisplatin
combination chemotherapy has modest activity in patients with extensive
CUPS and, at the schedule and dosage given, it is associated with moderate
toxicity.
相似文献
120.
To understand better the relationships between blood-group antigens and bacterial constituents, examples of 23 gram-negative bacteria (representing the 10 genera Citrobacter, Edwardsiella, Enterobacter, Escherichia, Klebsiella, Proteus, Pseudomonas, Salmonella, Serratia, and Shigella) were tested for the presence of Kl-like antigens by hemagglutination-inhibition (HAI) assays against both IgG and IgM anti-Kl. Saline-suspended whole organisms, cell-free culture media, and disrupted organisms were used to test for such antigens in, on, and secreted by the microorganisms examined. Disrupted organisms of an isolate of Shigella sonnei nonspecifically inhibited IgG anti-Kl as well as IgG antibodies of the specificities Kpb, Fya, S, and c. However, only Escherichia coli 0125:B15, subtype 12808, had specific K1-like activity (no activity with other IgG [(k, Kpb, Jka, Fya, S, c] and IgM [A, B, M, P1] antibodies). Disrupted organisms inhibited IgM but not IgG anti-K1 in the HAI assay. A second subtype, E. coli 0125:B15, subtype 12809, exhibited no K1-like activity. These findings support the report of K1 activity in cell-free broth cultures of E. coli 0125:B15 (subtype unspecified). Thus, although not all E. coli 0125:B15 possesses K1-like activity, the finding of such activity in at least one E. coli subtype confirms the idea that bacterial components may play a role in the production of naturally occurring antibodies directed against non-ABO red cell antigens. 相似文献